Savara Inc
NASDAQ:SVRA
Savara Inc
Other Current Assets
Savara Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Other Current Assets
$4.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
47%
|
CAGR 10-Years
16%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$4.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
$3.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$3.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$665.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
25%
|
CAGR 10-Years
29%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$349.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
11%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Other Current Assets?
Other Current Assets
4.8m
USD
Based on the financial report for Dec 31, 2024, Savara Inc's Other Current Assets amounts to 4.8m USD.
What is Savara Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
16%
Over the last year, the Other Current Assets growth was 82%. The average annual Other Current Assets growth rates for Savara Inc have been 21% over the past three years , 47% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet